44 results about "Co medication" patented technology

The invention belongs to the technical field of medicines, and particularly discloses application of fibronectin 1 (FN1) in treatment of mycobacterial infection. The invention finds that the FN1 has new application, and the survival of mycobacteria can be inhibited when the FN1 is independently applied; in a mycobacterium infection model, after the FN1 protein is exogenously added, the number of mycobacteria in macrophages is remarkably reduced; on the contrary, after the FN1 is knocked down, the number of mycobacteria in the macrophage is obviously increased. Further mechanism research shows that the FN1 affects release of reactive oxygen species (ROS) and cytokines by regulating a PI3K / AKT signaling pathway, and further removes mycobacteria in macrophages. From the perspective of host immunity, the invention discloses a mechanism that FN1 affects ROS (reactive oxygen species) and inflammatory response by regulating a PI3K / AKT signal channel so as to inhibit mycobacteria, and a new medicine is provided for treatment of mycobacteria infection. On the basis, FN1 can be independently used or combined with first-line antituberculosis drugs, and a new means is provided for solving the problem of drug resistance in mycobacterium infection treatment.

The present invention relates to a pharmaceutical composition for use in the treatment of both low-grade and high-grade glioblastoma in a human subject. The composition comprises a synergistic combination of the following active agents: R-Ketorolac, Bumetanide, and Niflumic acid. This specific combination is designed to exert a synergistic therapeutic effect against glioblastoma by targeting multiple molecular pathways involved in tumor progression, inflammation, and ion transport. In a further aspect of the invention, there is provided a method for selecting a subpopulation of glioblastoma subjects who are responsive to the aforementioned treatment. This method comprises identifying genetic profiles predictive of a favorable therapeutic response to the combined administration of R-Ketorolac, Bumetanide, and Niflumic acid.

The invention belongs to the field of biological medicine, and particularly relates to application of TPRA1 in the anti-tumor effect of oncolytic viruses. The invention provides the application of the oncolytic virus in preparation of the TPRA1 high-expression tumor medicine and the application of the TPRA1 accelerant in preparation of the oncolytic virus anti-tumor synergist or the drug resistance reversal agent for the first time. On the basis, the application of a substance for detecting the TPRA1 in preparation of products for oncolytic virus anti-tumor curative effect evaluation, oncolytic virus anti-tumor prognosis evaluation, tumor treatment scheme selection and / or tumor diagnosis or prognosis evaluation is provided for the first time; meanwhile, it is proved that the antitumor effect can be remarkably improved through combined medication of the oncolytic virus and the TPRA1 accelerant.

The application provides a combined medicine containing a nitrothiazolyl acid amide derivative and application thereof, and belongs to the field of chemical medicines. The combined medicine contains component A and component B which are administered simultaneously or separately and have the same or different specifications, and a pharmaceutically acceptable carrier. The component A is a nitrothiazolyl acid amide derivative shown in formula I, or a pharmaceutically acceptable salt thereof, or a crystal form thereof. The component B is a fatty acid, or a pharmaceutically acceptable salt thereof, or a crystal form thereof. The combined medicine is used for preventing and / or treating infections and related diseases. The combined medicine can produce a synergistic effect, is used for treating viral, bacterial and parasitic infections and related diseases, and has a good treatment effect. Meanwhile, the combined medicine has good safety in use, provides a new choice for clinically treating infections and related diseases caused by infections, and has a good application prospect.

The present invention addresses the problem of providing: an anti-CLDN4 / anti-CD137 bispecific antibody used in combination with a platinum-based drug for treatment of a target cancer; a pharmaceutical composition comprising said bispecific antibody; and a cancer treatment method involving administering, to a subject, an anti-CLDN4 / anti-CD137 bispecific antibody and a platinum-based drug.　In this invention, in a mouse bearing human CLDN4-expressing mouse cancer cells, the combined use of an anti-CLDN4 / anti-CD137 bispecific antibody and oxaliplatin exhibited a significant antitumor effect compared to the case of administering the anti-CLDN4 / anti-CD137 bispecific antibody or oxaliplatin alone. Furthermore, in a mouse bearing human CLDN4-expressing mouse cancer cells, an antitumor effect more effective than double therapy was confirmed in triple therapy in which an anti-CLDN4 / anti-CD137 bispecific antibody is additionally used with double therapy of oxaliplatin and an anti-VEGFR antibody. These results suggest that the combination of an anti-CLDN4 / anti-CD137 bispecific antibody and a platinum-based drug is effective in treatment of a CLDN4-expressing cancer.

This invention relates to the application of PWWP2B as a target in the preparation of drugs for the treatment of leukemia, belonging to the field of biomedical technology. To address the problem that traditional AML treatment targets lack tumor specificity and fail to meet clinical needs, this invention provides the application of PWWP2B as a target in the preparation of drugs for the treatment of leukemia. This invention demonstrates that PWWP2B is highly expressed in acute myeloid leukemia (AML) cells, and as a molecular marker, it can accurately distinguish AML from healthy individuals or non-leukemia patients. In vivo and in vitro experiments demonstrate that knocking out PWWP2B can significantly inhibit the proliferation and colony formation of AML cells, promote their differentiation and apoptosis, and inhibit the activity of leukemia cells in patients. This invention also reveals for the first time a novel use of the small molecule compound EZM0414 in the treatment of AML and its synergistic effect when used in combination with methyltransferase inhibitors.

This disclosure relates to a combination drug regimen comprising an anti-KMA antibody, IMiD / CELMoD, and a steroid. Such a combination may be used for the treatment of multiple myeloma.

The application discloses application of FTY720 as a PP2A phosphatase activator in preparation of a medicine for treating type I neurofibromatosis. The application first uses FTY720 for treatment of type I neurofibromatosis, and proves that FTY720 significantly inhibits formation of neurofibromas by non-specifically activating PP2A phosphatase. In-vivo experimental results show that FTY720 as a single drug can significantly inhibit tumor growth, and a synergistic effect is presented when FTY720 is combined with a MEK inhibitor, and tumor growth is almost completely inhibited. In-vitro cell experiments show that FTY720 as a single drug or in combination with MEKi treatment can inhibit tumor Schwann cells from forming tumor spheres, inhibit cell proliferation and migration, and induce tumor cell apoptosis. The application overcomes the drug resistance problem existing in the prior art MEK inhibitor, and provides a new treatment strategy for type I neurofibromatosis. FTY720 is an FDA-approved drug, and has good safety and drugability, and has high clinical conversion potential.

The invention relates to application of HDAC (histone deacetylase) inhibitor and Cathepsin B inhibitor combined medicine in lung cancer treatment, and belongs to the technical field of biological medicine. Research finds that histone deacetylase inhibitors (HDAC inhibitors, HDACIs) can promote invasion and migration of tumor cells by inducing epithelial-mesenchymal transition while inhibiting tumor growth, and side effects are generated. Therefore, in order to inhibit the side effect and enable the HDAC inhibitor to effectively exert the curative effect clinically, the invention provides a novel medicine combination mode, the HDAC inhibitor and the Cathepsin B inhibitor are combined for use, so that the antitumor activity of the HDAC inhibitor is retained, the tumor invasion and migration capability induced by the HDAC inhibitor is effectively inhibited, and the curative effect of the HDAC inhibitor is effectively exerted clinically. A new strategy is provided for precise treatment of solid tumors, and the method is verified in treatment of lung cancer.

The invention provides an SLC16A3 inhibitor based on ferroptosis regulation and application of the SLC16A3 inhibitor in lung adenocarcinoma, and relates to the technical field of biological treatment drugs. The SLC16A3 inhibitor is a drug MSC-4381, the drug MSC-4381 is an effective SLC16A3 inhibitor, the SLC16A3 inhibitor can be used for inhibiting lactic acid transporter SLC16A3, breaking the redox steady state of tumor cells, inducing ferroptosis and remarkably enhancing the curative effect of the drug gefitinib, and in an in-vivo and in-vitro model, cell proliferation, migration and invasion can be inhibited through SLC16A3 knock-down or pharmacological inhibition, so that the SLC16A3 inhibitor can be used for preventing and treating the tumor cells. The MSC-4381 and the gefitinib are combined to promote lipid peroxidation and iron ion accumulation, the tumor growth can be obviously delayed through drug combination of the MSC-4381 and the gefitinib, the effect can be partially reversed through the Ferrostatin-1, the ferroptosis-dependent mechanism of the MSC-4381 and the gefitinib is verified, and transcriptional regulation and control of the SLC16A3 by the HIF1A and influence on ferroptosis resistance are clear. The invention provides a feasible combined medication strategy, verifies the significant tumor inhibition effect of the HIF1A-SLC16A3 axis in cell and animal models, reveals the key effect of the HIF1A-SLC16A3 axis in lung adenocarcinoma drug resistance formation, and provides a new combined treatment strategy and a new molecular target.

Provided are methods for the treatment of SCLC patients by administering therapeutic amounts of lurbinectedin by intravenous infusion. Also provided are methods of treating cancer by administering lurbinectedin in combination with other anticancer drugs, in particular topoisomerase inhibitors. The invention further relates to the administration of lurbinectedin in combination with anti-emetic agents for effective control of symptoms related to nausea and vomiting, reduced lurbinectedin dosages to achieve a safer administration and an increase in the number of treatment cycles. Stable lyophilized formulations of lurbinectedin are also provided.

A pharmacovigilance method and system for combined drug use acquires multi-source information from electronic health records; estimates clinical symptom medication parameters based on a Bayesian engine; constructs a symptom network, calculates the betweenness centrality of each node, and identifies pivotal symptoms for adverse reaction propagation; calculates Bayesian factors for clinical symptom medication parameters, assesses the probability of adverse reaction occurrence and symptom severity, and generates a risk report. This invention captures the impact of drug interactions through a Bayesian hierarchical model, and utilizes the Horseshoe prior to effectively handle sparse data, reducing the false negative rate and improving signal detection sensitivity; secondly, it incorporates patient covariates and symptom network analysis to provide personalized risk assessment and key symptom alerts, improving the interpretability of conclusions and enhancing clinical relevance. Finally, it outputs an intuitive risk report to assist clinical decision-making, demonstrating strong practicality.

A combined drug of an estrogen receptor degrader and an AKT inhibitor and use thereof. The present invention pertains to the field of pharmaceuticals. The combined drug comprises an estrogen receptor degrader and an AKT inhibitor of the same specification or different specifications that are administered simultaneously or separately and a pharmaceutically acceptable carrier, can degrade estrogen receptors, inhibit cancer cell growth, exert a synergistic inhibitory effect, and significantly improve the effect of treating estrogen receptor-related diseases, and has good application prospects.

The invention relates to the technical field of tumor treatment drugs, in particular to a drug combination for treating CLDN18.2 + tumors and application of the drug combination. The invention provides a drug combination for treating CLDN18.2 + tumors. The drug combination comprises an antibody coupling drug and a neutrophil extracellular capture network inhibitor. The invention provides an innovative combined medication strategy, that is, a CLDN18.2 targeted ADC drug and a neutrophil elastin inhibitor Sivestat are combined for use, and the treatment efficiency of the drug in CLDN18.2 positive solid tumors is improved by effectively inhibiting formation of NETs and removing ADC binding obstacles. The strategy can significantly improve the tumor microenvironment, enhance the immune response and overcome the drug resistance of part of patients to ADC single-drug treatment, and has a clear targeting mechanism basis and a good clinical transformation prospect.

The invention provides application of taurochenodeoxycholic acid and / or chenodeoxycholic acid and polyinosinic acid combined medicine in preparation of medicine for preventing and / or treating melanoma, and belongs to the field of biological medicine. It is found for the first time that taurochenodeoxycholic acid and / or chenodeoxycholic acid can influence the tumor immune microenvironment by regulating and controlling the antigen presentation function of cDC1, and the treatment effect of polyinosinic-cytidylic acid is improved. The melanoma model experiment directly shows that the combination of chenodeoxycholic acid and polyinosinic-cytidylic acid can better inhibit tumor growth, can effectively promote CD8 + T cell infiltration in tumors, has more cDC1 infiltration in tumor tissues, shows a stronger inhibition effect on tumors, and can be used for preparing drugs for treating tumors. The pharmaceutical composition plays a synergistic role in treatment of melanoma, and provides a new choice for clinical treatment of melanoma.

The invention discloses a drug combination composition for resisting acute T lymphocytic leukemia and application, the drug combination composition for resisting acute T lymphocytic leukemia comprises an MCL1 inhibitor and afatinib, and the MCL1 inhibitor is S63845. The anti-acute T lymphocytic leukemia drug combination composition is applied to anti-tumor treatment. According to the present invention, the MCL1 inhibitor and the afatinib are combined, such that the significant apoptosis and pyroptosis can be induced, the MYC expression can be significantly reduced, and the purposes of T-ALL tumor cell killing and T-ALL treatment can be achieved.

The present application relates to the technical field of medicine, in particular to a kind of composition for treating IDH1 mutation and mutant drug resistance and application thereof, the composition is composed of AG120 and phosphatidyl ethanolamine (PE).The present application finds that the composition containing AG120 and PE can synergistically reduce the expression of IDH1 mutant carcinogenic metabolite 2-HG and inhibit tumor growth;And improve the therapeutic effect after IDH1 mutant solid tumor is resistant to AG120, can reduce the expression of IDH1 mutant drug-resistant tumor cell carcinogenic metabolite 2-HG and inhibit its tumor growth;The effect of combination group is obviously superior to the group of AG120 used alone.At the same time, the pharmaceutical composition is not found in the process of application treatment that mouse weight reduces and obvious drug toxicity.

The application relates to the technical field of medicines, in particular to a novel quinoline DKC1 inhibitor and application thereof. 23 H 26 ClN3O, a structure formula is shown as formula I. The compound can be directly and efficiently combined with an ASP125 site of DKC1 protein which is an important component of a telomerase, and effectively inhibit the pseudouridine synthase activity. Functional experiments show that the compound can significantly inhibit the proliferation ability of various DKC1 high-expression tumor cells by targeting inhibition of DKC1, and can produce better anti-tumor ability in combination with an ATR inhibitor, and exhibits potential value as a novel targeted therapeutic drug.

The invention belongs to the technical field of medicinal chemistry, and discloses a derivative small molecule containing an indole group and a triazine group and application of the derivative small molecule in preparation of an NAE / HDAC double-target inhibitor. The derivative small molecule containing the indole group and the triazine group disclosed by the invention is a derivative small molecule developed based on a rational pharmacophore fusion design strategy, and as a single-molecule multi-target inhibitor, the derivative small molecule can overcome the inherent technical defects of drug combination, retains the synergistic inhibition activity, and can be used for preparing a drug for preventing and treating diseases. The inhibition efficiency of part of derivative small molecules is superior to that of the existing NAE inhibitor and HDAC inhibitor combined medication.

The invention belongs to the technical field of biological medicines, and particularly relates to application of daptomycin in preparation of a non-small cell lung cancer EGFR-TKI drug resistance reversal agent. The invention discloses that daptomycin can effectively reverse drug resistance for the first time: in-vitro experiments show that evaluation is performed by adopting an HSA model of SynergyFinder software, and it is found that the drug combination synergy score of daptomycin and osimertinib in H1975 drug-resistant cells is 18.166, which indicates that daptomycin and osimertinib have a strong synergistic effect, and the drug resistance of daptomycin and osimertinib can be effectively reversed. Cloning formation experiments show that the cell proliferation inhibition rate of a drug combination group is increased by more than 80% compared with that of a single drug group, and a strong synergistic effect is achieved. An in-vivo experiment further verifies that the tumor volume of a combined drug group is reduced by about 80% compared with that of an osimertinib single drug group, the tumor weight is obviously reduced, drug-resistant relapse does not occur in a treatment period of 22 days, and meanwhile, the stability of the weight of a mouse shows that the safety is good. The invention provides a combined treatment scheme with high efficiency and safety for overcoming EGFR-TKI drug resistance, and has important clinical transformation value.

The application discloses application of a composition containing isovaleric acid and lenvatinib in preparation of anticancer drugs and belongs to the technical field of biological medicines.It is found for the first time that isovaleric acid and lenvatinib have a synergistic effect after being combined, and the anticancer activity of the composition containing isovaleric acid and lenvatinib can be significantly improved, especially the inhibitory activity on liver cancer cells in vitro is better.Then, through animal experiments, it is further verified that the combination of isovaleric acid and lenvatinib can synergistically inhibit the growth of liver cancer cells in mice.Therefore, the composition containing isovaleric acid and lenvatinib has a good application prospect in the prevention and treatment of hepatocellular carcinoma.

The application discloses a medicine composition and pharmaceutical use of a combination of a JNK inhibitor and a PARG inhibitor. The application discloses for the first time that the JNK inhibitor (such as BIRB 796) and the PARG inhibitor (such as PDD00017273) can improve the synergistic effect of treating gastric cancer, the two inhibitors have a synergistic effect when used in combination, have a synergistic effect, realize a significant improvement of an anti-tumor effect, and do not increase the toxicity to various organs by the combination, but rather reduce the dosage of various drugs, thereby reducing the side effects, and have a significant significance for the application of the combination of the PARG inhibitor and the JNK inhibitor to the treatment of gastric cancer.

The application discloses application of PAK4 inhibitor comp55 in preparation of a medicine for inhibiting formation of tumor-related fibroblasts, and belongs to the technical field of medicine application. The application first proposes the application of PAK4 inhibitor comp55 in preparation of the medicine for inhibiting formation of tumor-related fibroblasts, and provides a new scheme for the medicine for inhibiting formation of tumor-related fibroblasts. The application first proposes that PAK4 inhibitor comp55 inhibits formation of CAFs by targeting PAK4. The application first proposes that PAK4 inhibitor comp55 and vitamin D analogues are used in combination to synergistically inhibit formation of CAFs. The application first proposes that PAK4 inhibitor comp55 and anti-PD-1 antibodies are used in combination to synergistically inhibit formation of CAFs. The application first proposes that PAK4 inhibitor comp55, vitamin D analogues and anti-PD-1 antibodies are used in combination to significantly inhibit tumor growth, inhibit formation of CAFs, promote CD8 + T cell infiltration and IFN-gamma secretion.

The invention relates to the technical field of biological medicines, in particular to application of a CCR1 / 5 inhibitor Met-RANTES in inhibition of pathological pain of trigeminal nerves. According to the invention, CCR1 / 5 is taken as a therapeutic target of chronic pain, and a medicine which is remarkable in analgesic effect, small in side effect and capable of relieving chronic pain and improving pain mood is developed by combining the pharmacological function of an inhibitor Met-RANTES of CCR1 / 5. The Met-RANTES inhibits a central nervous system chemokine receptor CCRR1 / 5 in a targeted manner in a regular nasal administration manner, so that pathological mechanical pain-sensitive response and accompanying negative emotion caused by chronic compression of trigeminal nerves can be remarkably relieved, and pain feeling is relieved. In addition, the analgesic effect of the drug combination of the Met-RANTES and the carbamazepine is more obvious than that of the drug combination of the Met-RANTES and the carbamazepine which are independently used. The nasal delivery mode enables the medicine to directly reach the central nervous system, and reduces side effects of the whole body.

The invention belongs to the technical field of biological medicine, and discloses a marker for pancreatic cancer chemotherapy drug sensitivity evaluation and application thereof. According to the molecular marker for evaluating the sensitivity of the pancreatic cancer chemotherapeutic drug, the drug is a combined drug of gemcitabine and capecitabine, the molecular marker comprises a marker group 1 and a marker group 2, the marker group 1 is composed of hsa-miR-145, hsa-miR-489, hsa-miR-192, hsa-miR-221, hsa-miR-100, hsa-miR-630 and hsa-miR-141, and the marker group 2 is composed of hsa-miR-489, hsa-miR-192, hsa-miR-221, hsa-miR-100, hsa-miR-630 and hsa-miR-141. And the marker group 2 is composed of hsa-miR-760, hsa-miR-520b, hsa-miR-452, hsa-miR-18a and hsa-miR-139, and the marker group 2 is composed of hsa-miR-760, hsa-miR-520b, hsa-miR-452,

Contemplated cancer therapies comprise co-administration of aldoxorubicin with an immune therapeutic composition that preferably comprises a vaccine component and a cytotoxic cell component.

The invention relates to the technical field of biological pharmacy, in particular to a gemcitabine nano-particle, an anti-tumor combined medicine and application, and the gemcitabine nano-particle is composed of a gemcitabine core and a cell membrane covering the gemcitabine core; the cell membrane is derived from a CT26-PD-1 cell which is subjected to over-expression of PD-1 after genetic engineering modification; the particle size of the gemcitabine nano-particles ranges from 150 nm to 200 nm. The gemcitabine is coated by a PD-1 overexpressed tumor cell membrane, the enrichment capacity of the gemcitabine in tumors is enhanced by virtue of the interaction of PD-1 and PD-L1, and the biotoxicity and short blood half-life period of the gemcitabine are improved; by combining with a CD73 inhibitor AB680, precise targeted delivery and immune microenvironment regulation and control on the colorectal cancer are realized, and an efficient and low-toxicity innovative scheme is provided for tumor treatment.

The invention discloses a pharmaceutical composition of JNK inhibitor and PARG inhibitor combined medication and pharmaceutical application. The invention discloses for the first time that the JNK inhibitor (such as bentamamol) and the PARG inhibitor (such as PDD00017273) have the synergistic effect on improving the gastric cancer treatment effect, the two inhibitors have the synergistic effect when being combined for use, the anti-tumor effect is remarkably improved, toxicity to each organ is not increased through combined use, and the effect of treating the gastric cancer can be obviously improved through combined use of the JNK inhibitor (such as bentamamol) and the PARG inhibitor (such as PDD00017273). On the contrary, the dosage of various medicines is reduced, so that the toxic and side effects are reduced, and the obvious significance is realized on the gastric cancer resisting application of PARG inhibitor and JNK inhibitor combined medication.

The application discloses a new use of sildenafil and its salts in combination with ibuprofen. Through pharmacodynamics and toxicology experiments, the application first proposes and verifies that the combination of sildenafil and its salts (sildenafil citrate) and ibuprofen has a significant synergistic effect in treating inflammatory pain, and can effectively reduce the renal toxicity induced by long-term administration of ibuprofen. The application solves the problem that long-term or large-dose use of ibuprofen can induce significant renal toxicity, which seriously limits the long-term, standard and sufficient clinical application of ibuprofen. The composition provided by the application can enhance the analgesic effect of ibuprofen and reduce the renal toxicity of ibuprofen, and has important clinical conversion value and practical application prospect.

The invention provides application of taurochenodeoxycholic acid and / or chenodeoxycholic acid and PD-1 antibody combined medicine in preparation of medicine for preventing and / or treating melanoma, and belongs to the field of biological medicine. It is found for the first time that taurochenodeoxycholic acid and / or chenodeoxycholic acid can influence the tumor immune microenvironment and improve the treatment effect of the PD-1 antibody by regulating and controlling the function of cDC1. The melanoma model experiment directly shows that the combination of chenodeoxycholic acid and the PD-1 antibody can better inhibit tumor growth, and can effectively promote CD8 + T cell infiltration in tumor, so that more cDC1 infiltration exists in tumor tissue, the stronger inhibition effect on tumor is displayed, and the application of chenodeoxycholic acid and PD-1 antibody in tumor treatment is realized. The pharmaceutical composition plays a synergistic role in treatment of melanoma, and provides a new choice for clinical treatment of melanoma.